Comparison of nodal risk formula and MR lymphography for predicting lymph node involvement in prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 1, 2011, Pages 8-15

  Deserno, Willem M L L G ^a   Debats, Oscar A ^a   Rozema, Tom ^a   Fortuin, Ansje S ^b   Heesakkers, Roel A M ^a   Hoogeveen, Yvonne ^a   Peer, Petronella G M ^a   Barentsz, Jelle O ^a   Van Lin, Emile N J T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DEVENTER HOSPITAL   (Netherlands)

Author keywords

MR lymphography; Nodal risk formula; Prostate cancer; Regression analysis; USPIO

Indexed keywords

ADDED VALUES; DEPENDENT VARIABLES; GOLD STANDARDS; INPUT VARIABLES; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE; MR LYMPHOGRAPHY; NODAL RISK FORMULA; PROSTATE CANCERS; RECEIVER OPERATING CHARACTERISTIC ANALYSIS; REGRESSION MODEL; ULTRA-SMALL; USPIO;

BODY FLUIDS; IRON OXIDES; MAGNETIC RESONANCE; PARAMAGNETISM; PATHOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS;

DISEASES;

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHOGRAPHY; MAGNETIC RESONANCE LYMPHOGRAPHY; MAJOR CLINICAL STUDY; NODAL RISK FORMULA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

DEXTRANS; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; LYMPHATIC METASTASIS; LYMPHOGRAPHY; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 79961129222     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.05.043     Document Type: Article

References (29)

1. P.L. Nguyen, and A.V. D'Amico Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials J Clin Oncol 26 2008 2055 2056 author reply 2056-2057
2. M. Roach 3rd Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials J Clin Oncol 26 2008 3816 3817 author reply 3817-3818
3. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 53673
4. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
5. P. Bader, F.C. Burkhard, and R. Markwalder Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169 3 2003 Mar 849 854 (Pubitemid 36188105)
6. L. Cheng, H. Zincke, and M.L. Blute Risk of prostate carcinoma death in patients with lymph node metastasis Cancer 91 2001 66 73 (Pubitemid 32052615)
7. G.W. Hull, F. Rabbani, and F. Abbas Cancer control with radical prostatectomy alone in 1,000 consecutive patients J Urol 167 2 Pt 1 2002 Feb 528 534 (Pubitemid 34074521)
8. S.A. Joslyn, and B.R. Konety Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer Urology 68 2006 121 125 (Pubitemid 44037727)
9. A.D. Morris, A.L. Zietman, and A.F. Althausen The value of external beam radiation in node positive prostate cancer: A multivariate analysis Urol Oncol 6 2001 255 260 (Pubitemid 33065682)
10. M. Roach 3rd, C. Marquez, and H.S. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer [review] Int J Radiat Oncol Biol Phys 28 1994 33 37 (Pubitemid 24012852)
11. P.L. Nguyen, M.H. Chen, and K.E. Hoffman Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era Int J Radiat Oncol Biol Phys 74 2009 104 109
12. M.V. Meng, and P.R. Carroll When is lymph node dissection necessary before radical prostatectomy? A decision analysis J Urol 164 2000 1235 1240
13. R.A.M. Heesakkers, A.M. Hövels, and G.J. Jager MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study Lancet Oncol 9 2008 850 856
14. M.G. Harisinghani, J. Barentsz, and P.F. Hahn Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N Engl J Med 348 2003 2491 2499 (Pubitemid 36706536)
15. N.J.D. Nagelkerke A note on a general definition of the coefficient of determination Biometrika 78 1991 691 692
16. A.W. Partin, M.W. Kattan, and E.N.P. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localizes prostate cancer, a multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
17. P. Narayan, G. Fournier, and V. Gajendran Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer Urology 44 1994 519 524
18. M. Roach 3rd Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: Change you can believe in, or back to the future? In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009) Int J Radiat Oncol Biol Phys 75 2009 316 author reply 316
19. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114 (Pubitemid 23175983)
20. M.R. Cooperberg, J.W. Moul, and P.R. Carroll The changing face of prostate cancer J Clin Oncol 23 2005 8146 8151 (Pubitemid 46211547)
21. J.T. Bishoff, A. Reyes, and I.M. Thompson Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: Development of a system of patient selection Urology 45 1995 270 274
22. D.L. Bluestein, D.G. Bostwick, E.J. Bergstralh, and J.E. Oesterling Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer J Urol 151 1994 1315 1320 (Pubitemid 24121942)
23. R.E. El Galley, T.E. Keane, and J.A. Petros Evaluation of staging lymphadenectomy in prostate cancer Urology 52 1998 663 667 (Pubitemid 28440177)
24. A.M. Hövels, R.A.M. Heesakkers, and E.M. Adang Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT Eur Radiol 14 2004 1707 1712 (Pubitemid 39232905)
25. L. Salomon, A. Hoznek, and M.A. Lefrere-Belda Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients Eur Urol 37 2000 297 300 (Pubitemid 30122263)
26. R.A. Heesakkers, G.J. Jager, and A.M. Hövels Prostate cancer: Detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging Radiology 251 2009 408 414
27. R.W. Veltri, M.C. Miller, and G.J. O'Dowd Impact of age on total and complexed prostate specific antigen cutoffs in a contemporary referral series of men with prostate cancer/ Urology 60 Suppl 1 2002 47 52
28. J.J. Bauer, R.R. Connelly, and I.A. Sesterhenn Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy Cancer 79 1997 952 962 (Pubitemid 27089879)
29. P. Narayan, V. Gajendran, and S.P. Taylor The role of transrectal ultrasound-guided biopsy based staging, preoperative PSA and biopsy Gleason score in prediction of final pathological diagnosis in prostate cancer Urology 46 1995 205 212